Novartis has done a little spring cleaning, sweeping a phase 2 osteoarthritis prospect and first-in-human radioconjugate out of its pipeline after assessing evidence on the programs.

Novartis said it plans to invest $23 billion in the construction and expansion of U.S. facilities. The move comes after President Trump earlier this week threatened "major" tariffs on pharmaceuticals.

In 2022, Novartis said it would cut 8,000 jobs globally, Reuters reported, a move that would save the company $1 billion over the next two years. Additionally, the company spun off its generics ...

As a result, Moberg Pharma expects to have several alternate terbinafine suppliers secured in the near future. Each of these suppliers has the capacity to meet the company's global terbinafine demand.

Novartis is paying Generate:Biomedicines $65 million up front in an AI drug development deal, and milestone payments could exceed $1 billion.

A Novartis executive said “it’s too early to say” whether the company would submit an experimental myelofibrosis drug for approval this year, amid questions about the medicine’s data profile.

Key takeaways: Treatment efficacy was achieved by 76.67% of the continuous regimen group vs. 26.67% of the pulsed group (P = .001).The authors recommended daily, continuous usage of terbinafine in ...

Lamisil 250mg - 14 Tablets (Terbinafine) drug information. Find its price or cost, dose, when to use, how to use, side effects, adverse effects, substitutes . It is manufactured by Novartis India Ltd.